Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Funding
Details : The fundings will be used for the development of a unique bispecific antibody approach for treating Non-small Cell Lung Cancer (NSCLC), the most prevalent type of lung cancer in the United States.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 18, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?